Durvalumab is a treatment that helps the body\'s immune system to identify and attack cancer cells by binding to a protein called PD-L1. Studies show that durvalumab lowers the risk of cancer growing or spreading, and prolongs survival, when administered after chemotherapy and radiation therapy (‘chemoradiotherapy’) in patients with a type of lung cancer called stage III non-small-cell lung cancer (NSCLC) for whom surgery is not an option.Two antibody treatments have been developed that may help a patient\'s immune system to identify and attack cancer cells. Oleclumab binds to a protein on cancer cells called CD73, which prevents the production of adenosine, a chemical that obstructs the immune system from attacking the cancer. Monalizumab binds to NKG2A, a protein on immune cells that inhibits their ability to destroy cancer cells. Early studies suggest that combining either of these treatments with durvalumab may be better than durvalumab alone for slowing the growth and spread of cancer in patients with NSCLC.PACIFIC-9 is a study that aims to recruit approximately 999 patients with stage III NSCLC for whom surgery is not an option and who have completed chemoradiotherapy without the cancer growing or spreading. Patients will be randomly assigned in equal numbers to receive up to a year of treatment with durvalumab plus oleclumab, durvalumab plus monalizumab or durvalumab plus placebo. The primary measure of efficacy is the length of time that patients remain alive without the cancer growing or spreading for each combination versus durvalumab plus placebo.
Durvalumab是一种通过与称为PD-L1的蛋白质结合来帮助人体免疫系统识别和攻击癌细胞的治疗方法。研究表明,durvalumab可以降低癌症生长或扩散的风险,延长生存期,当在化疗和放疗('放化疗')后对一种称为III期非小细胞肺癌(NSCLC)的肺癌患者进行治疗时,手术不是一种选择.已经开发了两种抗体治疗方法,可以帮助患者的免疫系统识别和攻击癌细胞。Oleclumab与癌细胞上的一种叫做CD73的蛋白质结合,阻止腺苷的产生,一种阻止免疫系统攻击癌症的化学物质。Monalizumab与NKG2A结合,免疫细胞上的一种蛋白质,抑制它们破坏癌细胞的能力。早期研究表明,在NSCLC患者中,将这些治疗方法与durvalumab结合使用可能比单独使用durvalumab更好地减缓癌症的生长和扩散。PACIFIC-9是一项旨在招募约999名III期NSCLC患者的研究,这些患者不能选择手术,并且已经完成了放化疗而没有癌症生长或扩散。患者将被随机分配相同的数量,以接受durvalumab加oleclumab长达一年的治疗,durvalumab联合monalizumab或durvalumab联合安慰剂.疗效的主要衡量标准是每种组合与durvalumab加安慰剂相比,患者在没有癌症生长或扩散的情况下存活的时间长度。